VCM
ALXN

Virtue Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Virtue Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,308
Closed -$829K – 310
2020
Q4 		$829K Buy
5,308
+46
+0.9% +$5.91K 0.2% 141
2020
Q3 		$602K Buy
5,262
+863
+20% +$93.1K 0.15% 188
2020
Q2 		$494K Buy
+4,399
New +$467K 0.11% 188
2020
Q1 		– Sell
-2,329
Closed -$252K – 228
2019
Q4 		$252K Buy
+2,329
New +$249K 0.07% 215

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtue Capital Management's ALXN Position: Q1 2021 in Review

Virtue Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 5,308 shares — an estimated $829K sold.

Virtue Capital Management first reported a position in ALXN in Q4 2019 and held it in 4 quarters. The position peaked at $829K in Q4 2020. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Virtue Capital Management reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Virtue Capital Management sold 5,308 Alexion Pharmaceuticals shares in Q1 2021, an estimated $829K.
  • Virtue Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2019 and held it in 4 quarters.
  • Virtue Capital Management's Alexion Pharmaceuticals position peaked at $829K in Q4 2020.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Virtue Capital Management's 13F filing for Q1 2021, filed 13 May 2021.